Humans have a homologous population with nearly identical specificity, and although the cells tend to be more frequent in mice than humans, clinical trials are underway based on activating human iNKT cells to stimulate antitumor resp
Humans have a homologous population with nearly identical specificity, and although the cells tend to be more frequent in mice than
humans, clinical trials are underway based on activating human iNKT cells to stimulate antitumor resp
humans,
clinical trials are
underway based on activating
human iNKT cells to stimulate antitumor responses.